101P - Thymidylate synthetase (TYMS) expression is not predictive in patients with metastatic NSCLC treated with pemetrexed, cisplatin and bevacizumab in t...

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Oliver Gautschi
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors O. Gautschi1, S. Rothschild2, Q. Li3, S. Savic4, L. Bubendorf4, M. Brutsche5, L. Stalder3, N. Mach6, A. Ochsenbein7, R. Jaggi8
  • 1Klinik Für Onkologie, Luzerner Kantonsspital, 6004 - Luzern/CH
  • 2Medical Oncology, University Hospital Basel, 4000 - Basel/CH
  • 3Coordinating Center, SAKK, 3000 - Bern/CH
  • 4Pathology, University Hospital Basel, 4000 - Basel/CH
  • 5Pulmonology, Kantonsspital St. Gallen, 9000 - St. Gallen/CH
  • 6Oncology, Geneva University Hospital, 1211 - Geneva/CH
  • 7Medical Oncology, Bern University Hospital, 3000 - Bern/CH
  • 8Department Of Clinical Research, Bern University, 3000 - Bern/CH


Retrospective data suggest thymidylate synthetase (TYMS) expression as a predictive marker for pemetrexed activity in patients (pts) with advanced nonsquamous NSCLC. We prospectively measured TYMS by quantitative PCR (qPCR) in the phase II trial SAKK19/09 (NCT01116219).